AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35085318
Drug: Ultrasound-guided peripheral
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided peripheral intravenous catheter (UL PIVC)
Trial: 35085318
Drug: Vesicant doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vesicant doses (≥ 3 vs 0)
Trial: 32756843
Drug: Urea with
RxNorm normalized name: DermacinRx Urea with Salicylic Acid 39.5%-2% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urea with NBPT urease inhibitor
Trial: 32756843
Drug: Nitrogen treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrogen treatments
Trial: 34928698
Drug: Bamlanivimab (7000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bamlanivimab (7000 mg)
Trial: 34547193
Drug: Mirabegron 25
RxNorm normalized name: mirabegron 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 25 mg daily
Trial: 32930113
Drug: Kanglaite (KLT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kanglaite (KLT) injection combined with gefitinib
Trial: 32230721
Drug: Robuvit® (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robuvit® (300 mg/day) for 4 weeks
Trial: 34235560
Drug: Zilver PTX
RxNorm normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zilver PTX drug-coated stent
Trial: 39512761
Drug: Quadrivalent recombinant
RxNorm normalized name: INFLUENZA VACCINE,QUADRIVALENT RECOMBINANT (PF),SYRINGE,0.5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent recombinant influenza vaccine (RIV4)
Trial: 33417279
Drug: 2‐IOD (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2‐IOD (two implants in the canine regions bilaterally)
Trial: 32861144
Drug: HAART treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART treatment for 48 weeks in low microbial translocation (MT) group
Trial: 32861144
Drug: HAART treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART treatment for 48 weeks in high microbial translocation (MT) group
Trial: 35513910
Drug: Multi-strain probiotic
RxNorm normalized name: Digestive Advantage Multi-Strain Probiotic Ultra Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-strain probiotic (Vivomixx®) 4.4 g/day for 4 weeks
Trial: 35513910
Drug: Non-probiotic milk-powder
RxNorm normalized name: Milk powder
DrugBank: Skim milk (DB15546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-probiotic milk-powder placebo 4.4 g/day for 4 weeks
Trial: 32469166
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A (CsA) treatment
Trial: 33890158
Drug: Concurrent training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent training (PAR)
Trial: 36399673
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg once daily for three weeks
Trial: 32027842
Drug: m102.4 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m102.4 (1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg)
Trial: 32027842
Drug: m102.4 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m102.4 (20 mg/kg, two infusions 72 hours apart)
Trial: 32924183
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) training for PHNs
Trial: 35149322
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with prescription OUD
Trial: 32500344
Drug: Adjuvant transcatheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant transcatheter arterial infusion therapy (TAI)
Trial: 34078808
Drug: Limited-point plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limited-point plasma concentration analysis of CYP substrates in a cocktail drug
Trial: 35728621
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy
Trial: 35982449
Drug: Margarine without
RxNorm normalized name: MARGARINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Margarine without TFA (wTFA control group with 0.4 g TFA per 100 g margarine)
Trial: 35982449
Drug: Butter with
RxNorm normalized name: Suave Cocoa Butter with Shea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butter with rTFA (rTFA group with 6.3 g TFA per 100 g butter)
Trial: 32702252
Drug: HEA-enriched Cordyceps
RxNorm normalized name: CORDYCEPS SINENSIS
DrugBank: Ophiocordyceps sinensis (DB19288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEA-enriched Cordyceps cicadae mycelium (1.05 g granules once a day for 3 months)
Trial: 35372614
Drug: Sexual health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sexual health counseling based on cognitive-behavioral therapy (CBT), 8 sessions of 90 minutes each
Trial: 33858620
Drug: Tocilizumab (280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (280 mg single infusion)
Trial: 32731960
Drug: Cryotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryotherapy with mobilization (CM) twice per week for 5 weeks
Trial: 32046656
Drug: Stratified care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stratified care using the Keele STarT MSK development tool for risk-stratification and matched treatment options for low-, medium-, and high-risk patients.
Trial: 32046656
Drug: Stratified care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stratified care using matched treatment options.
Trial: 32046656
Drug: Stratified care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stratified care using the Keele STarT MSK tool and matched treatment options.
Trial: 36468569
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg daily for 2 weeks)
Trial: 36468569
Drug: Diclofenac (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (50 mg three times daily for 2 weeks)
Trial: 36468569
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of omeprazole and diclofenac (for 2 weeks)
Trial: 34057698
Drug: CPP-ACP cream
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CPP-ACP cream (daily single application)
Trial: 34122682
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C and Vitamin E combination
Trial: 32489082
Drug: Oral Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Chinese medicine
Trial: 32489082
Drug: Oral Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Chinese medicine (tablets and granules)
Trial: 32489082
Drug: Oral Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Chinese medicine (decoction and oral liquids)
Trial: 32489082
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral Chinese medicine and Western medicine
Trial: 36201354
Drug: ATI-2173 10
RxNorm normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATI-2173 10 mg
Trial: 36201354
Drug: ATI-2173 25
RxNorm normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATI-2173 25 mg
Trial: 36201354
Drug: ATI-2173 50
RxNorm normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATI-2173 50 mg
Trial: 34727277
Drug: Pre-treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment group
Trial: 34727277
Drug: Post-treatment group
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment group
Trial: 34264503
Drug: FKB238 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FKB238 15 mg/kg
Trial: 37945413
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion
Trial: 32992190
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) beyond 90 days (on clopidogrel)
Trial: 35303909
Drug: bamlanivimab (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bamlanivimab (700 mg, 2800 mg, or 7000 mg)
Trial: 32162239
Drug: Licorice flavonoid
RxNorm normalized name: Licorice Flavanoid Oil
DrugBank: Glycyrrhiza glabra (DB14312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licorice flavonoid oil (LFO) supplementation (300 mg daily for 16 weeks)
Trial: 36803892
Drug: Epidural corticosteroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural corticosteroid injection
Trial: 33851448
Drug: 80 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/day nano-curcumin
Trial: 32492712
Drug: D-dimer >2,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-dimer >2,500 ng/mL
Trial: 33555982
Drug: Standard insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard insulin pump therapy
Trial: 33559438
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment at 5-6 local acupoints and 3-4 distal acupoints, retained for 30 min, three times a week for 8 weeks.
Trial: 33559438
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture treatment with shallow needling technique at non-acupoint, retained for 30 min, three times a week for 8 weeks.
Trial: 32279619
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment for acute ischemic stroke
Trial: 34916068
Drug: Sertraline (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (n = 106) for 8 weeks
Trial: 34916068
Drug: Bupropion (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (n = 37) for 8 weeks after sertraline nonresponse
Trial: 32664244
Drug: PATCH self-assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PATCH self-assessment
Trial: 35579104
Drug: Oral care
RxNorm normalized name: Oral Care Q4 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral care tablet containing kiwifruit powder (intervention II)
Trial: 36175917
Drug: Low-dose naltrexone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose naltrexone (LDN) administered for 12 weeks, followed by an additional 12 weeks for all participants.
Trial: 33592280
Drug: Magnetic enteric-coated
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetic enteric-coated tablet containing diclofenac sodium
Trial: 33592280
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (before domperidone administration)
Trial: 35894933
Drug: Glimepiride 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 0.5 mg once daily
Trial: 35474624
Drug: CBT4BN (internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT4BN (internet-based cognitive-behavioral therapy)
Trial: 35474624
Drug: CBTF2F (face-to-face
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBTF2F (face-to-face cognitive-behavioral therapy)
Trial: 33989559
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks combined with cetuximab 400 mg/m2 intravenously (initial loading dose) followed by 250 mg/m2 intravenously weekly.
Trial: 33989559
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks combined with cetuximab 400 mg/m2 intravenously followed by 250 mg/m2 intravenously weekly.
Trial: 34705542
Drug: 3.0 g
RxNorm normalized name: LACTIC ACID 23.0 g in 1 L TOPICAL SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 g of FO n3 supplementation
Trial: 33299400
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current stimulation (tDCS) plus physical therapy
Trial: 35245011
Drug: PEG-rhGH 0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-rhGH 0.20 mg/kg/w
Trial: 35245011
Drug: daily rhGH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily rhGH 0.28 mg/kg/w
Trial: 32746639
Drug: Bright white
RxNorm normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright white light (BWL) for 30 minutes daily for 8 weeks
Trial: 32746639
Drug: Dim red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dim red light (DRL) for 30 minutes daily for 8 weeks
Trial: 32294620
Drug: Control with
RxNorm normalized name: Azo Bladder Control With Go Less
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control with intentional hydration (1 L of water the previous night, 500 mL 60 min before intervention, and 1 mL for each 1 g of body mass lost immediately after intervention)
Trial: 36286665
Drug: Glucocorticosteroid hormones
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucocorticosteroid hormones (GCS), specifically dexamethasone, used as an anti-inflammatory treatment for critically ill patients with COVID-19.
Trial: 32311799
Drug: Chemotherapy regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimens combined with trastuzumab
Trial: 34396874
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg 1 hour before surgery
Trial: 33427559
Drug: Increased dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased dietary phosphorus intake (100 mg)
Trial: 34486986
Drug: Istradefylline 40
RxNorm normalized name: istradefylline 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Istradefylline 40 mg/day
Trial: 35200040
Drug: Warfarin, clopidogrel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin, clopidogrel, and aspirin
Trial: 36307892
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) - 5 fractions of 8 Gy
Trial: 33331206
Drug: SHR0534 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR0534 at doses of 10, 25, 50, or 100 mg
Trial: 33331206
Drug: SHR0534 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR0534 at 5 mg
Trial: 35798138
Drug: Cassia fistula
RxNorm normalized name: CASSIA FISTULA FRUIT
DrugBank: Cassia fistula fruit (DB15860)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cassia fistula syrup (CFS)
Trial: 33766820
Drug: Standard breakthrough
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard breakthrough medication administered by healthcare professionals
Trial: 32310680
Drug: 0.05% w/w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% w/w ECa 233 gel
Trial: 35984704
Drug: CT900 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT900 at a dose of 12 mg/m2/q2Wk
Trial: 32482970
Drug: Guanfacine Extended
RxNorm normalized name: Guanfacine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine Extended Release (GXR) 1-7 mg/d
Trial: 32789935
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBOT) adjunctive to conventional therapy, 30 sessions, twice daily over 3 weeks (group A)
Trial: 33915011
Drug: Discharge care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discharge care bundle including medication reconciliation, counselling session and documentation transfer to primary care physician (PCP)
Trial: 33971837
Drug: Specific vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific vaccines (Polio, BCG, DPT (1-3), Measles)
Trial: 32144493
Drug: Spot urinary
RxNorm normalized name: Cold Spot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spot urinary sodium excretion (high: UNa+ > 50 or low: ≤ 50 mEq/L) at 2 h from furosemide administration
Trial: 33065643
Drug: Chemotherapy (CT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CT) consisting of 2 cycles of docetaxel plus cisplatin and 5-fluorouracil (DCF)
Trial: 32135413
Drug: Pegbovigrastim (IMR)
RxNorm normalized name: pegbovigrastim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegbovigrastim (IMR) treatment (2.7 mL of Imrestor)
Trial: 32135413
Drug: Control (CON)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (CON) treatment (2.7 mL of 0.9% saline)
Trial: 33471429
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) with conventional therapy (systemic antibiotics and trazodone)
Trial: 33471429
Drug: Sham therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham therapy (laser/LEDs off) with conventional therapy (systemic antibiotics and trazodone)
Trial: 33471429
Drug: Sham therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham therapy (laser/LEDs off)
Trial: 34876098
Drug: No-treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment group
Trial: 33370348
Drug: Cysteamine 450mg
DrugBank: Cysteamine (DB00847)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteamine 450mg twice daily
Trial: 34088727
Drug: Bronchial artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchial artery embolisation (BAE) associated with medical therapy
Trial: 34746903
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg
Trial: 33055588
Drug: Vaccine group
RxNorm normalized name: MENINGOCOCCAL OLIGOSACCHARIDE VACCINE GROUP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine group (VG) - 1 mg each of three epitope peptides injected postoperatively 10 times weekly followed by 10 times biweekly.
Trial: 34092822
Drug: SPN-812 400-mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPN-812 400-mg/day
Trial: 34092822
Drug: SPN-812 600-mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPN-812 600-mg/day
Trial: 34518679
Drug: PfSPZ Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ Vaccine (4.5×10^5, 9.0×10^5, or 1.8×10^6 doses)
Trial: 34518679
Drug: PfSPZ Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ Vaccine (1.8×10^6 dose)
Trial: 34518679
Drug: PfSPZ Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ Vaccine (9.0×10^5 dose)
Trial: 35254888
Drug: dd-MVAC (dose-dense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dd-MVAC (dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin)
Trial: 33454768
Drug: Early anti-androgen
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early anti-androgen treatment
Trial: 33454768
Drug: Late anti-androgen
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late anti-androgen treatment
Trial: 33095658
Drug: Microcurrent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcurrent therapy (active device) for 3 hours per day for 4 weeks
Trial: 36011679
Drug: Microcurrent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcurrent therapy
Trial: 35361646
Drug: Probiotic yoghurt
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic yoghurt (300 g/day containing 106 CFU/g Lactobacillus acidophilus and Bifidobacterium lactis)
Trial: 35361646
Drug: Plain yoghurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain yoghurt (300 g/day)
Trial: 34693434
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g of orthodontic force (Group B)
Trial: 34716979
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (pegylated liposomal doxorubicin [40 or 50 mg/m2], topotecan [1.25 mg/m2], paclitaxel [80 mg/m2], or gemcitabine [1000 mg/m2])
Trial: 33076866
Drug: Genotypic resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotypic resistance testing (GRT) to inform onward treatment
Trial: 35904580
Drug: Caffeine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (200 mg, oral)
Trial: 32307624
Drug: Full-dose ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose ketamine (0.5 mg kg‐1 initial bolus, 10 mcg kg‐1 min‐1 infusion)